Anti-cD20scFv/CD80/CD28/zeta specific T lymphocytes eradicate primary chronic lymphocytic leukemia cells in vitro / 中国应用生理学杂志
Chinese Journal of Applied Physiology
; (6): 436-439, 2010.
Article
en Zh
| WPRIM
| ID: wpr-301543
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To construct anti-CD20scFv/CD80/CD28/zeta recombinant gene modified T cells, test its effectiveness of eradicating CD20 positive primary chronic lymphocytic leukemia (CLL) cells and provide a promising tool for tumor adoptive immunotherapy.</p><p><b>METHODS</b>The recombinant vectors were transduced into PA 317 cells and high titer retroviruses were obtained to infect human peripheral blood T lymphocytes. Resistant T cells were obtained by G418 selection for one week. Then transduced T lymphocytes and primary CLL cells were co-cultured. The status of primary chronic lymphocytic leukemia cells were observed by microscope. The level of IL-2 and IFN-gamma in the culture medium were measured.</p><p><b>RESULTS</b>Primary T cells expressing anti-CD20scFv/IgGFc/CD80/CD28/zeta could be constructed successfully. These T cells were able to lyse CD20+ targets and secrete high levels of IL-2 (1301.00 pg/ml) and IFN-gamma (602.18 pg/ml) in vitro.</p><p><b>CONCLUSION</b>(1) Recombinant gene modified T cells can be constructed successfully. (2) Recombinant gene modified T cells can specially kill CD20 positive primary CLL cells in vitro.</p>
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Patología
/
Retroviridae
/
Células Tumorales Cultivadas
/
Linfocitos T
/
Transfección
/
Leucemia Linfocítica Crónica de Células B
/
Inmunoterapia Adoptiva
/
Interferón gamma
/
Interleucina-2
/
Antígeno B7-1
Límite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Applied Physiology
Año:
2010
Tipo del documento:
Article